S X Zhang1, J Sima, C Shao, J Fant, Y Chen, B Rohrer, G Gao, J-x Ma. 1. Department of Medicine, The University of Oklahoma Health Science Center, 941 Stanton L. Young Blvd., BSEB 328B, Oklahoma City, OK 73104-5043, USA.
Abstract
AIMS/HYPOTHESIS: Retinal vascular leakage is an early pathological feature in diabetic retinopathy and can lead to macular oedema and loss of vision. Previously we have shown that plasminogen kringle 5 (K5), an angiogenic inhibitor, inhibits retinal neovascularisation in the rat model of oxygen-induced retinopathy (OIR). The purpose of this study was to examine the effect of K5 on vascular leakage in the retina. METHODS: Neonatal rats were exposed to hyperoxia to induce OIR. Diabetes was induced in adult rats by injecting streptozotocin. Vascular permeability was measured by Evans blue method. Expression of vascular endothelial growth factor (VEGF) was evaluated using immunohistochemistry and western blot analysis. RESULTS: Rats with OIR and diabetes showed abnormal vascular hyperpermeability in the retina and iris. Intravitreal injection of K5, reduced vascular permeability in both animal models, but did not affect permeability in normal rats. K5 reduced vascular permeability at doses substantially lower than that required for inhibition of retinal neovascularisation. The K5-induced reduction in vascular permeability correlated with its down-regulation of VEGF expression in the retina. Moreover, K5 inhibited IGF-1-induced hyperpermeability, which is known to arise through up-regulation of endogenous VEGF expression. However, K5 had no effect on the hyperpermeability induced by injection of exogenous VEGF. CONCLUSIONS/ INTERPRETATION: Very low doses of K5 reduce pathological vascular leakage in the retina. K5 thus has therapeutic potential in the treatment of diabetic macular oedema. This effect can be ascribed, at least in part, to the down-regulation of endogenous VEGF expression.
AIMS/HYPOTHESIS: Retinal vascular leakage is an early pathological feature in diabetic retinopathy and can lead to macular oedema and loss of vision. Previously we have shown that plasminogen kringle 5 (K5), an angiogenic inhibitor, inhibits retinal neovascularisation in the rat model of oxygen-induced retinopathy (OIR). The purpose of this study was to examine the effect of K5 on vascular leakage in the retina. METHODS: Neonatal rats were exposed to hyperoxia to induce OIR. Diabetes was induced in adult rats by injecting streptozotocin. Vascular permeability was measured by Evans blue method. Expression of vascular endothelial growth factor (VEGF) was evaluated using immunohistochemistry and western blot analysis. RESULTS:Rats with OIR and diabetes showed abnormal vascular hyperpermeability in the retina and iris. Intravitreal injection of K5, reduced vascular permeability in both animal models, but did not affect permeability in normal rats. K5 reduced vascular permeability at doses substantially lower than that required for inhibition of retinal neovascularisation. The K5-induced reduction in vascular permeability correlated with its down-regulation of VEGF expression in the retina. Moreover, K5 inhibited IGF-1-induced hyperpermeability, which is known to arise through up-regulation of endogenous VEGF expression. However, K5 had no effect on the hyperpermeability induced by injection of exogenous VEGF. CONCLUSIONS/ INTERPRETATION: Very low doses of K5 reduce pathological vascular leakage in the retina. K5 thus has therapeutic potential in the treatment of diabetic macular oedema. This effect can be ascribed, at least in part, to the down-regulation of endogenous VEGF expression.
Authors: A M Ryan; D B Eppler; K E Hagler; R H Bruner; P J Thomford; R L Hall; G M Shopp; C A O'Neill Journal: Toxicol Pathol Date: 1999 Jan-Feb Impact factor: 1.902
Authors: Guoquan Gao; Yan Li; Stephen Gee; Andrew Dudley; James Fant; Craig Crosson; Jian-xing Ma Journal: J Biol Chem Date: 2002-01-08 Impact factor: 5.157
Authors: K Miyamoto; S Khosrof; S E Bursell; R Rohan; T Murata; A C Clermont; L P Aiello; Y Ogura; A P Adamis Journal: Proc Natl Acad Sci U S A Date: 1999-09-14 Impact factor: 11.205
Authors: L E Smith; E Wesolowski; A McLellan; S K Kostyk; R D'Amato; R Sullivan; P A D'Amore Journal: Invest Ophthalmol Vis Sci Date: 1994-01 Impact factor: 4.799
Authors: L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park Journal: N Engl J Med Date: 1994-12-01 Impact factor: 91.245
Authors: Andrea L Moyer; Raniyah T Ramadan; Billy D Novosad; Roger Astley; Michelle C Callegan Journal: Invest Ophthalmol Vis Sci Date: 2009-03-05 Impact factor: 4.799
Authors: Ji Jin; Kevin K Zhou; Kyoungmin Park; Yang Hu; Xun Xu; Zhi Zheng; Puneet Tyagi; Uday B Kompella; Jian-xing Ma Journal: Invest Ophthalmol Vis Sci Date: 2011-08-05 Impact factor: 4.799
Authors: Kyoungmin Park; Ying Chen; Yang Hu; Aaron S Mayo; Uday B Kompella; Richard Longeras; Jian-xing Ma Journal: Diabetes Date: 2009-06-02 Impact factor: 9.461
Authors: Mykhailo M Guzyk; Artem A Tykhomyrov; Victor S Nedzvetsky; Irina V Prischepa; Tatiana V Grinenko; Lesya V Yanitska; Tamara M Kuchmerovska Journal: Neurochem Res Date: 2016-06-02 Impact factor: 3.996
Authors: M A Ihnat; J E Thorpe; C D Kamat; C Szabó; D E Green; L A Warnke; Z Lacza; A Cselenyák; K Ross; S Shakir; L Piconi; R C Kaltreider; A Ceriello Journal: Diabetologia Date: 2007-05-17 Impact factor: 10.122